Drug Stock More Than Doubled Today; FAANG Rumors Sink GameStop

Plus, analysts downgrade Amgen ahead of earnings

Managing Editor
Jan 28, 2019 at 2:47 PM
facebook X logo linkedin

The Dow is getting wrecked today as Caterpillar (CAT) and chip stocks sell off. Biotech name Amgen, Inc. (NASDAQ:AMGN) and video game retailer GameStop Corp. (NYSE:GME) are under pressure, but drugmaker Avalon GloboCare Corp (NASDAQ:AVCO) has doubled in value today. Below, we'll take a look at what's moving the shares of AMGN, GME, and AVCO.

AMGN Gets Downgraded Ahead of Earnings

This morning, Evercore ISI downgraded Amgen to "in line," citing the cheaper generic drug competition coming from rivals such as Novartis AG. The downgrade comes one day before the company's fourth-quarter earnings report. At last check, AMGN was down 4.1% to trade at $190.72, taking the stock below its year-to-date and year-over-year breakeven levels. 

The options pits are as evenly split as they could be. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows speculative players have bought to open 2,919 puts in the last 10 sessions, compared to just 2,917 calls. However, the resultant put/call volume ratio of ranks in the 72nd percentile of its annual range, meaning puts have been bought to open over calls at a quicker-than-usual clip ahead of earnings.

GME Rally Paused by Apple Competition

GameStop stock is down 2.4% to trade at $15.52, after reports surfaced that Apple (AAPL) is planning a Netflix-like subscription service for video games. Despite the drop today, GME still boasts a 23.4% year-to-date gain thanks to buyout buzz, and the damage today appears to be contained by its 20-day moving average. 

The mood in the options pits has leaned bearishly. ISE/CBOE/PHLX data shows GME with a 10-day put/call volume ratio of 2.38, which ranks in the 79th percentile of its annual range. Echoing that, GME has seen more than 7,000 puts change hands today -- two time the average afternoon volume, and nearly twice the number of calls exchanged.

Cancer Development Sends AVCO Skyrocketing 

Sitting at the top of the Nasdaq today is Avalon GloboCare stock, up an incredible 104% to trade at $8.63, after the company's subsidiary Genexosome Technologies announced the development of a saliva-based bio-marker for its oral cancer therapy. AVCO has now tripled already in 2019, and tapped a record high of $13.50 on Jan. 22. 


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI